IBX Phase 2 Clinical Trial Update

Key points

• Phase 2 clinical Trial work orders signed and startup activities underway
• MagSense® investigational product manufacturing complete and ready for distribution
• Imaging protocol finalized with advanced quantitative MRI techniques

Full summary

Imagion Biosystems Limited (ASX: IBX) has provided an update on its Phase 2 clinical trial for the MagSense® HER2 Imaging Agent. The company has signed work orders with key contract research organizations (CROs) and initiated startup activities. Manufacturing of the investigational product is complete, and distribution logistics are in place. The imaging protocol has been finalized, incorporating advanced quantitative MRI techniques. The trial is expected to be completed in 18-24 months, with interim analyses anticipated after the initial cohort and the second group of subjects.